Achieving Value in Cancer Care

Video

This video explores the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level while maintaining optimal care for cancer patients.

With the rising costs of targeted agents, immunotherapies, and combination treatment strategies, creating value while maintaining optimal care for cancer patients is of critical importance.

In this video, Daniel R. Gomez, MD, of MD Anderson Cancer Center, discusses the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level without sacrificing high levels of care to patients.

Gomez gave a presentation on this topic at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content